On Monday, pharmaceutical giant Eli Lilly announced a price reduction for its renowned weight-loss drug Zepbound. This decision was put into motion approximately a month after the company secured an agreement with the Trump administration to decrease medication costs.
The new pricing model will entail a $50 discount for each once-a-month single vial of the 2.5-, 7.5-, 10-, 12.5-, and 15-milligram doses purchased through LillyDirect, the brand's digital health care platform. Additionally, the 5-milligram dosage will see a reduction of $100. The updated prices will span from $299 for the lowest dosage to $449 for the maximum dosage.
The pricing adjustment on Zepbound comes in response to mounting political demands for Eli Lilly to render its weight-loss medication line more economical. The initiative follows a White House conference in November, where Lilly's CEO David Ricks and President Trump disclosed strategies to enhance affordability and accessibility of the company's weight-loss medication range.
As part of the agreement, from next April [pending FDA approval], Zepbound and the obesity drug Orforglipron, will be capped at a monthly rate of $50 for benefit recipients under Medicare. Lilly also agreed to implement a more equitable pricing structure across developed nations for their future medication releases. In return, the Trump administration will shield Lilly from tariffs for three years and exempt them from future pricing regulations.
Despite a modest decline of about 2% amidst general market setbacks on Monday, Eli Lilly shares have risen by over a third in value in 2025, with the company achieving an all-time high last week.